Nicolas Serandour, CEO of Advanced Oncotherapy #AVO, visited the Proactive Investors studio to add some extra detail to their recent announcement that they’ve secured £37.4mln of fresh funding – £30mln of this coming from a new Chinese investor.
Home » Advanced Oncotherapy (AVO) » Nicolas Serandour, CEO of Advanced Oncotherapy #AVO talks to Andrew Scott at Proactive Investors